Minerva Neurosciences financials
$3.35−1.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $41.2M | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | $41.2M | — | — | — | — |
| Gross margin | — | — | — | — | — | 100.0% | — | — | — | — |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M | $1.8M | -$75.9M | -$51.7M | -$41.2M | -$30.2M |
| Net income | -$293.4M | $1.4M | -$30.0M | -$32.1M | -$49.9M | $1.9M | -$72.2M | -$50.2M | -$31.5M | -$31.0M |
| Net margin | — | — | — | — | — | 4.7% | — | — | — | — |
| Diluted EPS | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 | $0.40 | $-14.80 | $-10.32 | $-6.64 | $-7.92 |
| EBITDA | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.3M | $2.0M | -$75.7M | -$51.7M | -$41.2M | -$30.2M |
| Operating cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M | -$33.8M | -$43.4M | -$41.9M | $3.1M | -$25.7M |
| Free cash flow | -$13.5M | -$19.6M | -$14.8M | -$24.7M | — | — | — | — | $3.0M | — |
| Diluted shares | 8.5M | 7.6M | 6.5M | 5.3M | 5.3M | 5.1M | 4.9M | 4.8M | 4.7M | 3.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.3M | $21.4M | $40.9M | $36.1M | $60.8M | $25.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M | $57.6M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M | $5.0M |
| Shareholders' equity | -$140.7M | -$25.7M | -$28.5M | -$20.0M | $8.0M | $52.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology